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The regulation ofhistamine release from oxyntic mucosa is complexbecause oftwo potential
sources of histamine: mast cells and enterochromaffin-like (ECL) cells. A gastrin-responsive
histamine pool was identified in the rat oxyntic mucosa two decades ago, but these ECL cells
from the rat have not yet been isolated or characterized in vitro. In vivo studies in canine and
human mucosa have been more difficult because ofthe high content ofhistamine in mast cells.
Using enzyme-dispersed canine oxyntic mucosal cells, we have studied regulation ofhistamine
release from a mast cell-depleted fraction prepared by sequential elutriation and density
gradient. Histamine-like immunoreactivity was demonstrated, using peroxidase-anti-peroxi-
dase immunohistochemistry. After short-term culture, histamine was released in response to
gastrin, cholecystokinin, carbachol, and forskolin. Somatostatin potently and effectively inhib-
ited the response to gastrin. The cultures used for these studies also contained somatostatin
cells, and, furthermore, the response to gastrin was enhanced by incubation with monoclonal
antibodies to somatostatin. The latter findings suggested that somatostatin was acting in these
cultures by a paracrine route. This pattern contrasts with that obtained in previous studies of
canine oxyntic mucosal mast cells.
HISTAMINE RELEASE FROM OXYNTIC MUCOSAL STORES
The discovery of the dramatic effect of H2 blockers on gastrin-stimulated acid
secretion [1] left no question that the delivery of histamine from oxyntic mucosal
stores to the parietal cell was central to the physiologic control of acid secretion.
Controversy has surrounded the regulation ofhistamine cell function, however, and
one major reason for divergent views and confusion is that the oxyntic mucosal
histamine is stored in two cell types [2].
OxynticMucosalMast Cells
In some species, such as dog and man, the oxyntic mucosa contains a large number
of mast cells, and a correlation exists between histamine content and the content of
mast cells [3,4], suggesting that mast cells account for a large component ofmucosal
histamine.
In ourstudies, we found that dispersed canine oxynticcellscontained considerable
histamine, and the histamine content was highest in the small-cell fractions of the
elutriator separation [5]. Subsequent density gradients performed on the small-cell
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elutriator fractions revealed a close correlation between the distribution ofhistamine
and of content of mast cells. There was no obvious enrichment of histamine in
fractions thatwere enriched in endocrine or endocrine-like cells [5,6]. These findings
supported the view that mast cells account for a major portion of the histamine
present in the canine oxyntic mucosa.
In our studies of the factors regulating histamine release from mast cell-enriched
fractions of oxyntic mucosal cells, these fractions were placed in suspension culture
overnight [7]. The responsiveness of mast cells under these conditions was estab-
lished by demonstrating stimulation ofhistamine release by the plant lectin concana-
valin A (Con A) and in response to cross-linking IgE receptors using passive
sensitization and an antibody toIgE or ragweed antigen. Histamine release was also
induced with the calcium ionophore A23187 and the phorbol ester 3-TPA. Despite
manipulations of culture conditions, gastrin and carbachol failed to stimulate
histamine release. Furthermore, in studies combining elutriation with density gradi-
ent separation of the small-cell fraction, 1251-[Leu15]-G17 binding correlated nega-
tivelywith the number ofmast cells [6]. Thus both functional and radioligand studies
argued against the presence of gastrin receptors on oxyntic mast cells. No other
agonists of physiologic interest have been identified. It is possible that mast cells,
which lie in close proximity to mucosal nerves, release histamine in response to
neuronal neurotransmitters; however, such release mechanisms have thus far not
been defined. Although oxyntic mast cells can participate in responses to allergens
presented to gastric mucosa [8], whether the high number ofmast cells in the oxyntic
mucosa reflects a role in inflammatory responses or in the regulation of acid
secretion remains to be established.
Histamine ECL Cells in the Rat
Studies with rat oxyntic mucosa have most clearly demonstrated the presence of
histamine in non-mast cell stores. In this species, gastrin stimulates the formation of
histamine by inducing the activity of histidine decarboxylase [9,10]. In addition,
studying a perfused rat stomach model, Sandvik, Waldum, and co-workers have
demonstrated that gastrin induces histamine release in parallel with increases in acid
secretory function [11]. Also in the rat, a dramatic trophic effect of gastrin on the
histamine-containing cells in rat oxyntic mucosa is evident in studies utilizing very
high doses of potent antisecretory agents, such as omeprazole or ranitidine [12].
When given in high doses for 20 days, these agents induce achlorhydria, hypergas-
trinemia, and hyperplasia of oxyntic mucosal enterochromaffin-like (ECL) cells;
antrectomy reversed the hypergastrinemia and ECL-cell hyperplasia [12].
There is little question that these oxyntic ECL cells in the rat mucosa contain
immunoreactivity for both histamine and histidine decarboxylase (HDC). Further-
more, in response to prolonged treatment of rats with omeprazole, parallel increases
are found in the number ofcells staining with histamine-like and HDC-like immuno-
reactivity, in histamine content, and in the number of cells with the silver-staining
properties of ECL cells [12].
Although the histamine-containing cells ofthe rabbit gastric mucosa have received
less detailed study, histamine is also present in an endocrine cell [13]. Furthermore,
gastrin has been demonstrated to induce histamine release from rabbit gastricglands
in vitro [14,15].
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HistamineECL Cells in theHuman and Canine Oxyntic Mucosa
There has been considerable controversy regarding the presence of histamine-
ECLcells in the human and canine fundic mucosa, because ofboth the high content
of mast cells and the lower number of ECL cells; however, Hakanson et al.
demonstrated histamine-like immunoreactivity in endocrine cells in both species
[13]. Furthermore, the early hypotheses that histamine stores in canine and human
are released in response to gastrin have been confirmed by recent studies, using a
very sensitive assay and carefully quantifying degradation products [16].
Gastrin receptors also appear to exert a trophic effect on ECL cells in humans.
The sustained hypergastrinemia that occurs in the Zollinger-Ellison (ZE) syndrome
and in atrophic gastritis [17-19] is associated with ECL-cell hyperplasia. Ofinterest
is the fact that formation of ECL-cell carcinoids occurs with sustained hypergas-
trinemia in the settingofZE syndrome, butonlyinthe subsetofpatientswith MEN-I
(multiple endocrine neoplasia, type I). In contrast, ECL-cell hyperplasia without
dysplasia or carcinoid formation occurs in sporadic ZEsyndrome [19,20]. In asimilar
fashion, amongexperimentalmodelsofsustainedhypergastrinemia, carcinoidforma-
tion uniquely occurs in the rat, butonly at the end ofthe two-yearlife span and at an
age when other endocrine cell neoplasia also occurs [19,20]. Therefore, it appears
that a carcinoid requires interaction between hypergastrinemia and the altered
regulation of endocrine cell proliferation linked to the defect on chromosome 11 in
MEN-I [21] or found in aged rats [19].
Isolation and Characterization ofCanine OxynticMucosalHistamine-ECL Cells
In studies using a similar approach to those mentioned above for canine mucosal
cells, we also investigated cells isolated from rat oxyntic mucosa [22] and found the
presence of histamine, histidine decarboxylase, and DOPA decarboxylase activity in
cells of light density. In the canine oxyntic mucosa, markers for enterochromaffin
cells (DOPA-decarboxylase and serotonin) and endocrine cells (somatostatin and
glucagon) are present in cells oflight and intermediate density, respectively [6,23]. In
the dog, however, histamine content in this region of the density gradient is low.
These contrasts between rat and canine oxyntic cells supported the notion that
dramatic differences existed in the cells storing histamine in the oxyntic mucosa of
different species. It is now clear, however, that these differences are ofaquantitative,
rather than a qualitative, nature.
The findings that endocrine cells containing histamine are present in the canine
gastric mucosa [13] and that gastrin induced histamine release in vivo in the dog [16]
prompted our further efforts to develop approaches for identifying and characteriz-
ing gastrin-responsive histamine cells in the canine cell preparations [24]. For these
studies aimed at non-mast cell histamine stores, we adapted methods originally used
for studying somatostatin cells in short-term culture [25]. In contrast to our initial
report [25], however, we recognized that mast cells from the small-cell elutriator
fraction were also adherent to the culture substrate under these conditions. There-
fore, we used step density gradients ofalbumin to prepare fractions largely depleted
of mast cells ( <0.6 percent). In these studies, cellular histamine was demonstrated,
using peroxidase-anti-peroxidase (PAP) immunohistochemistrywith rabbit antibody
8431, kindly provided by Hakanson, Sundler, and co-workers [13]. Although there
were occasional mast cells in our cultures after density step separation, mast cells
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accounted for a smallproportion ofthe cells positive forhistamine-like immunoreac-
tivity. Unfortunately, with the low initial content of non-mast cell histamine cells,
even after density step separation and culture, the non-mast cell histamine cells
accounted for only about 3 percent ofthe adherent cells.
We focused efforts initially on developing methods for the sensitive measurement
of histamine and on adapting culture methods to allow for the reduction of basal
histamine release. The latter was accomplished by using type IV collagen (Matri-
gelT') as a substrate [24], and initially culturing cells in 2 percent, rather than 10
percent, serum, followed by a final three-hour incubation in serum-free medium.
Using canine cells prepared, separated, and cultured in this fashion, gastrin and
cholinergic agents increased histamine release in a time-dependent fashion. A
response to gastrin and cholinergic agents was evident at two minutes [24]. Gastrin
stimulated histamine release in a dose-dependent fashion, with an apparent ED50 of
about 0.2 nM. In contrast to our findings with mast cells, forskolin stimulated
histamine release from the mast cell-deleted fraction [24]. As an important control,
we compared data from these mast cell-depleted cultures with the pattern of
histamine release obtained from mast cell-containing preparations cultured in
suspension [7,26] or cultured on Matrigel under conditions identical to the mast
cell-depleted preparation [24]. Consistently, the mast cell preparations lacked
detectable responses to gastrin or cholinergic agents.
The Gastrin/CCKReceptorModulatingHistamineRelease
Gastrin and the octapeptide of cholecystokinin (CCK) were of equal efficacy in
stimulating histamine release from our preparation of non-mast cells from canine
oxyntic mucosa. These findings thus suggested a receptorthatwas comparable to the
gastrin receptor on the canine parietal cell [27,28]. In our studies, the receptor
antagonist L365,260 has a low potency for the canine receptor on both histamine-
ECL and parietal cells [unpublished observations], a finding similar to that reported
for the cloned receptor expressed in COS cells [28]. In contrast, in rabbit gastric
glands, L365,260 was about 50 times more potent than L364,718 in inhibiting
gastrin-stimulated histamine release [29]. Recently, the gastrin receptor on the
ECL-carcinoid cells has been cloned [30] and found to be comparable to the B-type
gastrin receptor originally cloned from the canine parietal cell. Thus, present data
indicate that the ECLcell and the parietal cell possess B-type gastrin receptors. For
as yet unexplained reasons, species variability exists in the relative affinities of
subtype-specific antagonists.
Inhibition ofOxyntic MucosalHistamineRelease
We found that the somatostatin analog SMS 201-995 very effectively inhibited
gastrin-stimulated histamine release from the mast cell-depleted fractions, with the
ID50 (dose producing 50 percent inhibition) being 3 x 10-10 M. The response to
gastrin was significantly enhanced by treatment with the monoclonal antibody S6 to
somatostatin. These cultures also contain somatostatin cells, and this result sug-
gested that somatostatin in these cultures was producing "paracrine" inhibition of
histamine release. In contrast to this very effective inhibition ofhistamine release by
somatostatin, much higher concentrations ofsomatostatin were required to produce
less efficacious inhibition of canine parietal cell function [31]. The high potency for
somatostatin inhibition of histamine release, the magnitude of this inhibitory re-
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sponse, and the demonstration ofparacrine inhibition in our cultures all point to the
importance of inhibition of histamine release as a component of the in vivo
antisecretory action of somatostatin. Previous findings with rat stomach in vivo and
rabbit gastric glands have indicated dramatic inhibition by somatostatin of oxyntic
mucosal histamine release [32,33].
Thus, data obtained studying canine gastric mucosa also indicate a population of
histamine-containing non-mast cellsthat release histamine in response togastrin and
cholinergic agents, with somatostatin producing inhibition of probably physiological
importance.
GASTRIN RECEPTORS: WHAT IS PHYSIOLOGIC?
From the vantage point of the studies utilizing isolated canine oxyntic mucosal
cells, it is difficult to avoid the conclusion that gastrin receptors are present on
several cell types, including parietal cells, somatostatin cells, and histamine-
containing endocrine cells. It is possible that gastrin actions at these different sites
are related in variable degrees to enhancement of secretory function, a trophic
action, or a differentiative effect. The important question regarding the relative
physiological importance of these different actions ofgastrin cannot be determined
with present data. Several lines ofevidence indicate, however, that gastrin receptors
on the parietal cell are functional in intact mucosa, at least under certain circum-
stances. For example, Ruiz and Michelangeli have found that, in the presence of
cimetidine, gastrin enhances the response to dbcAMP [34]. In neonatal rats, Acker-
man [35] found a dissociation between gastrin- and histamine-stimulated acid
secretion; the acid secretory response to exogenous pentagastrin was detectable at an
age of 14 days, whereas response to exogenous histamine did not become detectable
until age 19 to 22 days. Furthermore, the response togastrin at 14daysofagewas not
blocked by H2 blockers, providing further evidence that a component of gastrin
action in vivowas independent ofhistamine, and, therefore, presumablymediated by
gastrin receptors on the parietal cell itself. We confidentlyconclude that a functional
gastrin receptor exists on parietal cells, but present data do not indicate the
component ofthe acid secretory effects ofgastrin that reflects interaction with these
parietal cell receptors.
It is possible that the ability ofgastrin to stimulate the parietal cell and to induce
histamine release are both physiologically relevant effects, but that other functions
may be activated by these receptors instead ofor in addition to the acute regulation
of acid secretory mechanisms. The gastrin effect on either of these cell types may
reflect trophic actions and/or maintenance of cell differentiation. For example,
gastrin has been reported to induce expression of the H+/K+-ATPase messenger
RNA in parietal cells [36] and to induce histamine decarboxylase activity in the rat
oxyntic ECL [37]. Approaches are needed to determine the physiologic importance
of these differentiative effects in comparison to the effects ofgastrin that stimulate
acid secretionviaeitherinduction ofhistamine release ordirect activationofparietal
cell receptors.
THE THEME: REDUNDANT CONTROL MECHANISMS REGULATE THE
ACID SECRETORY RESPONSE
The physiologic importance ofthe inhibitoryparacrine circuit mediatedbyoxyntic
mucosal somatostatin on parietal and histamine ECL cells requires further elucida-
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tion. Studies with in vitro preparations have provided evidence that oxyntic somato-
statin plays a role in acid feedback inhibition ofacid secretion [38]. Activators ofthis
inhibitory paracrine circuit remain to be established, but CCK is a leading candidate
[39,40]. Present data suggest the importance of somatostatin inhibition of ECL-cell
histamine release.
An emerging recurrent theme is that considerable redundancy exists in the
pathways regulating acid secretion. Most likely the consequences ofacid hypersecre-
tion or acid hyposecretion, from a standpoint of phylogeny, must be sufficient to
dictate overlapping control circuits that serve to increase the probability that control
will be maintained. We surmise that the multiple receptors for gastrin on parietal
cells, histamine-ECL cells, and somatostatin cells will each demonstrate effects of
physiologic orpathophysiologic importance. Critical processes such as the regulation
of acid secretion require redundant control circuits. A challenge confronting future
investigation in this field will be to sort out the physiologic or pathophysiologic
settings inwhich each ofthese receptors affects regulatory processes.
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